Mehriar Shokri
1, Bahador Bagheri
2, Alireza Garjani
3, Bahram Sohrabi
1*, Afshin Habibzadeh
4, Babak Kazemi
1, Ali Akbar Movassaghpour
51 Cardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
2 Cancer Research Center and Department of Pharmacology, Faculty of Medicine, Semnan University of Medical Sciences, Semnan, Iran.
3 Department of Pharmacology, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.
4 Medical Education Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
5 Hematology Research Centre, Tabriz University of Medical Sciences, Tabriz, Iran.
Abstract
Purpose: Toll-like receptors (TLR) are well known components of
the innate immune system. Among them, TLR4 is related to the inflammatory
processes involved in atherosclerotic plaque formation. Our purpose was to
compare the monocytic expression of TLR4 following implantation of drug-eluting
(DES) and bare stents (BMS).
Methods: In this
study, patients with chronic stable angina undergoing elective percutaneous
coronary intervention (PCI) in ShahidMadani Heart Hospital, Tabriz, Iran were
included. Ninety-five patients receiving DES and 95 patients receiving BMS were
selected between 2012 and 2014.Everolimus eluting stents were implanted for DES
group. Both groups received similar medications and procedure. Blood samples
were taken before PCI, 2 hours and 4 hours after termination of PCI. Expression
of TLR4 on monocytes was measured using flowcytometry. Patients were matched
for age, sex and coronary artery disease risk factors, but not for TLR4
expression rate before PCI.
Results: A significant
difference was seen between DES and BMS in TLR4 expression before (21.3±2.8%
vs. 15.5±2.7%; P< 0.05) and four hours after PCI (30.1 ± 3.3% vs 39.2
± 3.2%, P< 0.05). Due to the unmatched rate of TLR4+ expression
before PCI, we measured the percentage of increase in TLR4 expression between
groups. DES compared to BMS significantlycaused less increase in the TLR4
expression (50.23%±10.03% vs. 446.35%±70.58%, p<0.001).
Conclusion: Our findings suggest thateverolimuseluted from the
stents can decrease PCI induced increase in the TLR4 expression on the surface
of monocytes.